Skip to main content

Day: May 30, 2022

With 38.7% CAGR, Virtual Reality in Healthcare Market Worth USD 6.2 Billion by 2029

According to Fortune Business Insights, the global virtual reality in healthcare market size is projected to reach USD 6.20 billion by 2029, at a CAGR of 38.7% during the forecast period; Pious and Pico Interactive Inc. Collaborate to release 3.0 for Psychologists Pune, India, May 30, 2022 (GLOBE NEWSWIRE) — The virtual reality in healthcare market size stood at USD 459.0 million in 2021. The market is estimated to surge from USD 628.0 million in 2022 to USD 6.20 billion by 2029 at 38.7% CAGR during the forecast period. Fortune Business Insights™ has deep-dived these inputs in its latest research report, titled, “Virtual Reality (VR) in Healthcare Market Forecast, 2022-2029.” According to the analysis, virtual reality has become trendier in the healthcare sector to boost the treatment, planning, and diagnosis of persons with addiction,...

Continue reading

Protein Bar Market Striking 6.1% CAGR During 2022-2029 | Trend for On-the-go Breakfast to Bolster Growth Potentials

Companies covered in protein bar market are General Mills Inc. (U.S.), The Simply Good Foods Company (U.S.), The Kellogg Company (U.S.), Clif Bar & Company (U.S.), Glanbia Plc. (Ireland), GNC Holdings Inc. (U.S.), Mars, Incorporated (U.S.), Mondelez International (U.S.), POST HOLDINGS INC. (U.S.), Amway Corp. (U.S.), The Bountiful Company (U.S.) and Others Pune, India, May 30, 2022 (GLOBE NEWSWIRE) — The global protein bar market size stood at USD 4.54 billion in 2021. The market is anticipated to grow from USD 4.68 billion in 2022 to USD 7.07 billion by 2029 at 6.1% CAGR during the forecast period. Fortune Business Insights™ has deep-dived these inputs in its latest research report, titled, “Protein Bar Market, 2022-2029.” According to the analysis, a palpable trend for ready-to-eat (RTE) protein sources among the millennial...

Continue reading

Exercise of call BANKN13 PRO (NO0010797319)

Bank Norwegian ASA has exercised its right to call BANKN13 PRO (NO0010797319) on the first possible call date, 30 May 2022. The call rate is 100.00. Exercise of the call without reissuance by Bank Norwegian ASA has been approved by the Norwegian Financial Supervisory Authority.Contact persons: CEO and CFO, Klara Lise Aasen; phone +47 47635583; kaa@banknorwegian.no Head of Treasury, Mats Benserud; phone +47 95891539; mbe@banknorwegian.noThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Continue reading

Nexstim to Present at Redeye Growth Day 2022

Press release, Helsinki, 30 May 2022 at 11 AM (EEST) Nexstim to Present at Redeye Growth Day 2022 Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) CEO Mikko Karvinen will be taking part in Redeye Growth Day 2022 in Stockholm on Thursday 2 June 2022. A pre-recorded presentation is already available at Nexstim’s event space. An extensive Q&A session will be live broadcasted at the Redeye Growth Day 2022 event space on 2 June at 11:05 CEST (12:05 EEST). Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases...

Continue reading

Multiple Sclerosis Drugs Market Size & Trends 2022 – 2028 [CAGR 3.9%] | Industry Share, Growth by Fortune Business Insights

According to Fortune Business Insights, the global Multiple Sclerosis Drugs Market size is projected to reach USD 33.17 billion in 2029, at CAGR of 3.9% during forecast period; Increasing R&D in Neurology to Boost Market Growth: Fortune Business InsightsTM Pune, India, May 30, 2022 (GLOBE NEWSWIRE) — The global multiple sclerosis drugs market size was worth USD 23.68 billion in 2021. The market valuation is projected to increase from USD 25.43 billion in 2022 to USD 33.17 billion by 2029 at a CAGR of 3.9% during 2022-2029. In recent years, the incidence of multiple sclerosis has increased significantly. According to the Multiple Sclerosis International Federation, the number of multiple sclerosis patients reached 2.8 million in 2020, up from 2.3 million in 2013. Increasing federal funding and accelerated R&D efforts to...

Continue reading

Statkraft AS – Contemplating NOK green bond issues

Statkraft AS, rated A-/BBB+(Stable/Stable) by S&P and Fitch, has mandated Danske Bank, DNB Markets, Handelsbanken Capital Markets and SEB as Joint Bookrunners, to arrange a virtual investor meeting at 9:15 CEST on Tuesday 31 May 2022. Statkraft will give a company presentation and present its Green Finance Framework. Subject to market conditions, one or several NOK denominated senior unsecured green bond issues with expected tenor(s) of 5-10 years and expected combined size of NOK 3-5 billion may follow. SEB has acted as Sole Structuring Advisor for Statkraft’s Green Finance Framework which has obtained the highest possible shading of Dark Green and governance score of Excellent from Cicero Shades of Green. For further information, please contact: Statkraft AS; Stephan Skaane, Head of front office, phone +47 905 13 652

Continue reading

Sydbank share buyback programme: transactions in week 21

        Company Announcement No 23/2022Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk30 May 2022  Dear Sirs Sydbank share buyback programme: transactions in week 21On 2 March 2022 Sydbank announced a share buyback programme of DKK 425m. The share buyback commenced on 7 March 2022 and will be completed by 30 December 2022. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback programme:  Number...

Continue reading

Stellantis and Toyota Expand Partnership with New Large-size Commercial Van Including an Electric Version

Stellantis and Toyota Expand Partnership with New Large-size Commercial Van Including an Electric VersionStellantis and Toyota Motor Europe (TME) announce a new agreement on large-size commercial vans for the European market The new large-size van completes TME’s compact and mid-size van line-up under the existing partnership and strengthens Stellantis’ light commercial vehicle (LCV) scale in Europe in line with its Dare Forward 2030 objectives TME’s customers will benefit from Stellantis’ cutting-edge, zero-emission technology in each LCV segment supplied by StellantisAMSTERDAM / BRUSSELS, May 30, 2022 – Stellantis N.V. and Toyota Motor Europe N.V. (TME) today announced the expansion of their existing partnership with an agreement for a new large-size commercial van, including a battery electric version. The new vehicle marks the...

Continue reading

Vitamin D Testing Market Size [2022-2029] worth USD 871.7 Million | exhibiting a CAGR of 4.9%

According to Fortune Business Insights, the global Vitamin D Testing Market size is projected to reach USD 871.7 Million in 2029, at CAGR of 4.9% during forecast period; F. Hoffmann-La Roche Launched Cobas Infinity Edge to Boost Operational Efficiencies Pune, India, May 30, 2022 (GLOBE NEWSWIRE) — The Vitamin D Testing Market Size stood at USD 600.2 million in 2021. The market is anticipated to rise from USD 625.0 million in 2022 to USD 871.7 million by 2029 at 4.9% CAGR during the forecast period. Fortune Business Insights™ has deep-dived these inputs in its latest research report, titled, “Vitamin D Testing Market, 2022-2029.” According to an analysis, the demand for point-of-care testing kits will be pronounced across emerging and advanced economies. Some factors, such as lower turn-around time, fewer needs for professional...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.